Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

Hepatitis C virus (HCV)–infected patients with cirrhosis are historically a difficult‐to‐treat population and are at risk of hepatic decompensation. In the phase 2 COSMOS study that evaluated simeprevir (HCV NS3/4A protease inhibitor) + sofosbuvir (HCV nucleotide analogue NS5B polymerase inhibitor)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawitz, Eric, Matusow, Gary, DeJesus, Edwin, Yoshida, Eric M., Felizarta, Franco, Ghalib, Reem, Godofsky, Eliot, Herring, Robert W., Poleynard, Gary, Sheikh, Aasim, Tobias, Hillel, Kugelmas, Marcelo, Kalmeijer, Ronald, Peeters, Monika, Lenz, Oliver, Fevery, Bart, De La Rosa, Guy, Scott, Jane, Sinha, Rekha, Witek, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Viral Hepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297873/
https://www.ncbi.nlm.nih.gov/pubmed/26704148
http://dx.doi.org/10.1002/hep.28422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297873/
https://www.ncbi.nlm.nih.gov/pubmed/26704148
http://dx.doi.org/10.1002/hep.28422

Ejemplares similares